In the present study, the prevalence of NAFLD in PCOS patients with obesity was 75.61%, and the levels of liver CAP as well as ALT and AST activities in PCOS patients with obesity were significantly higher than those in controls, which further confirms that PCOS could exacerbate hepatic steatosis and liver function damage. The gene discussed is GPT; the disease is obesity due to melanocortin 4 receptor deficiency.